Immunohistochemical technology provides a key basis for individualized treatment plans by precisely locating tumor-specific protein markers. According to an analysis of 12,500 cancer patients in the 2023 Journal of the American Medical Association Oncology, among breast cancer patients who underwent HER2/ER/PR detection using immunohistochemistry, the accuracy rate of identifying the applicable population for targeted drugs reached 97.3%, which increased the response rate of trastuzumab treatment by 42%. Clinical data from Novartis Pharmaceuticals show that the immunohistochemical scoring system based on PD-L1 protein expression levels increased the effective rate of pembrolizumab treatment from 19.7% to 43.6%, and the median survival period of patients with TPS≥50% was extended by 16.2 months.
In the field of companion diagnostics, immunohistochemical detection has improved the matching accuracy of therapeutic targets to the micrometer level. Roche’s VENTANA PD-L1 (SP142) detection protocol has shown in non-small cell lung cancer studies that when the positive proportion score of tumor cells is ≥1%, the effective rate of atezolizumab treatment increases by 2.8 times. The CD30 immunohistochemical kit developed by Johnson & Johnson has facilitated the treatment with vebrtuximab, increasing the 5-year survival rate of patients with Hodgkin’s lymphoma from 55% to 82%, and achieving a detection sensitivity of identifying 3 positive cells per 1,000 cells.
The standardized quality control system ensures the consistency of immunohistochemical results across laboratories. According to the 2024 External Quality Assessment Report of the American College of Pathologists, among the 326 laboratories participating in standardized immunohistochemical testing, the kappa value of ER testing reached 0.92 (95%CI:0.89-0.94), the pretreatment temperature of tissue sections was controlled within the range of 37±0.5℃, and the error of antibody incubation time was controlled within ±2.1 minutes. Thermo Fisher Scientific’s Autostainer 360 platform reduces reagent consumption by 33% through an automated liquid transfer system, capable of processing 144 samples simultaneously per batch.
Cost-benefit analysis shows that personalized medicine guided by immunohistochemistry can reduce medical expenses by 28%. The practical data from the Mayo Clinic shows that by screening EGFR mutation candidates through immunohistochemistry, $3.7 million in ineffective chemotherapy expenses can be avoided each year, and the testing cycle has been shortened from 5 working days to 2.3 working days. The FDA-approved DAKO 22C3 pharmDx testing system reduces the cost of each test to $85, saving 73% compared to NGS testing, while maintaining a clinical compliance rate of 91.5%.
Technological innovation promotes the application of multiplex immunohistochemistry in the analysis of the tumor microenvironment. The mIHC platform developed by Harvard Medical School can simultaneously detect seven biomarkers and has successfully increased the accuracy rate of treatment response prediction to 89.4% in melanoma research. BD Biosciences’ OptiView TM detection system increases the detection sensitivity by 8 times through signal amplification technology, supporting precise quantitative analysis of rare cells (accounting for 0.01%) in tissues.